Pharmacogenetic analysis of the Programmed cell death 6-interacting protein in Chinese individuals by Smieszkol, Kamila
Page | 1 
 
  
 
 
Pharmacogenetic analysis of the Programmed cell death 6-interacting protein in 
Chinese individuals 
By 
Kamila Smieszkol 
 
 
 Supervisors:  
                      Prof. Vera Ribeiro Marques (University of Algarve) 
 
                      Prof.  Zhao Qian Liu (Central South University) 
 
 
 
 
Page | 2 
 
1. Contents 
2. List of abbreviations ................................................................................................................................ 4 
3. Abstract: .................................................................................................................................................. 7 
4. INTRODUCTION ....................................................................................................................................... 8 
4.1. Pharmacogenetics .....................................................................................................................8 
4.2. Principles of pharmacogenetics ................................................................................................9 
4.3. Cancer .................................................................................................................................... 10 
4.4. Lung cancer ............................................................................................................................ 18 
4.4.1. Non-small cell lung carcinoma ...................................................................................... 19 
4.4.2. Stages of cancer ............................................................................................................. 21 
4.4.3. Stages, diagnose and spread of Non-Small Cell Lung Cancer ........................................ 22 
4.5. Platinum- based chemotherapy ............................................................................................. 28 
4.5.1. Gene polymorphisms affecting outcome of cancer therapy (cancer pharmacogenetics)30 
4.5.2. Platinum Resistance ...................................................................................................... 31 
4.6. SNP (Single Nucleotide Polymorphism) ................................................................................. 33 
4.7. Gene ....................................................................................................................................... 34 
4.7.1. PDCD6IP (The programmed cell death 6 interacting protein) ...................................... 34 
4.8. Polymerase chain reaction (PCR) ........................................................................................... 36 
4.8.1. Primers .......................................................................................................................... 39 
4.8.2. PCR-RFLP (Restriction Fragment Length Polymorphism) .............................................. 40 
4.8.3. Real-time PCR) ............................................................................................................... 41 
4.9. DNA electrophoresis .............................................................................................................. 41 
4.10. Data analysis .......................................................................................................................... 43 
4.10.1. The Hardy–Weinberg equilibrium ................................................................................. 43 
4.10.2. Minor allele frequency .................................................................................................. 46 
4.10.3. SPSS- Binary Logistic Regression.................................................................................... 46 
4.10.4. Stratification .................................................................................................................. 47 
5. Objective ............................................................................................................................................... 48 
6. MATERIALS AND METHODS .................................................................................................................. 49 
6.1. Ethics approval ....................................................................................................................... 49 
6.2. Tagging SNP selection ............................................................................................................ 53 
6.3. DNA extraction and genotyping procedure ........................................................................... 54 
6.3.1. Genomic DNA extraction ............................................................................................... 54 
6.3.2. Procedures of genotyping by PCR-RELP: ....................................................................... 55 
6.3.3. Statistical analysis .......................................................................................................... 58 
7. RESULTS ................................................................................................................................................. 59 
Page | 3 
 
7.1. Patient Characteristics ........................................................................................................... 59 
7.2. Prevalence of the PDCD6IP rs3183982 SNP ........................................................................... 61 
7.3. Relation of PDCD6IP gene polymorphism with platinum-based chemotherapy response ... 61 
8. CONCLUSION ......................................................................................................................................... 67 
9. References: ............................................................................................................................................ 69 
 
 
Page | 4 
 
2. List of abbreviations 
 
G6PD  glucose-6-phosphate dehydrogenase  
GS  growth signals 
GF  growth factor 
PDGF  platelet-derived growth factor 
PDCD6IP  the programmed cell death 6 interacting protein 
PCD  programmed cell death 
PDCD6 the programmed cell death 6 gene 
E2F  transcription factor 
TGF- β transforming growth factor beta 
Bcl-2  B-cell lymphoma 2 
Apaf-1  apoptotic peptidase activating factor 1 
P53  tumour protein 
VEGF  Vascular Endothelial Growth Factor 
HIF  Hypoxia inducible factor  
CAM  cell adhesion molecules 
NSCLC non-small cell lung cancer 
SCLC  small cell lung cancer 
EAC  erythema annulare centrifugum 
ESCC  esophageal squamous cell carcinoma 
TKI   tyrosine kinase inhibitor  
SNP  single nucleotide polymorphism 
MRI  magnetic resonance imaging 
CT  computer tomography 
CAT  computed axial tomography 
PET  pulmonary function test 
EUS  endoscopic ultrasound 
AUC  area under the concentration 
CTR1  copper transporter receptor  
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ATP7 A/B P-type adenosine triphosphate 
GSH  glutathione 
HDAC  histone deacetylases inhibitor 
SAHA  pan-histone deacetylase inhibitor 
ESCRT endosomal sorting complex required for transport 
TF  transcript factor 
NF-kB  nuclear factor-kappaB  
HCC  hepatocellular carcinoma 
MVB  multivesicular body  
EGFR  epidermal growth factor receptor 
RTK  receptor tyrosine kinase 
PCR   polymerase chain reaction 
FISH  in situ hybridization 
GFP  green fluorescent protein 
dNTPs  deoxynucleoside triphosphates  
PCR   polymerase chain reaction 
PT-PCR real-time polymerase chain reaction 
PFGE  pulsed field gel electrophoresis 
DGGE  Denaturing Gradient Gel Electrophoresis 
TGGE  temperature Gradient Gel Electrophoresis 
SDS  sodium dodecyl sulphate 
PAGE  polyacrylamide gel electrophoresis 
RFLP  Restriction Fragment Length Polymorphism 
MNP  multiplex nested 
V  voltage 
I  current 
R  resistance 
MAF  minor allele frequency 
ECOG  Eastern Cooperative Oncology Group 
ECOG PS Eastern Cooperative Oncology Group Performance Status 
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RECIST Response Evaluation Criteria in Solid Tumours 
CR  complete response 
PR  partial response 
SD  stable disease 
PD  progressive disease 
cTNM  Clinical diagnostic staging 
UICC  Union Internationale contre le Cancer 
TAE  Tris-acetate-EDTA 
Tris-HCL tris(hydroxyethyl)amino methane 
EDTA  Ethylenediaminetetraacetic acid 
HWE  Hardy - Weinberg Equilibrium 
CI  confidential interval 
OR  odd ratio 
HWE P p value for Hardy-Weinberg test 
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3. Abstract: 
Introduction: 
Pharmacogenetics is the study of germline genetic variation resulting in altered absorption, 
distribution, metabolism and excretion associated with the efficacy or toxicity of a drug, or 
affecting drug interaction with the target protein. Cancer is one of the top ten leading causes of 
death globally. Moreover lung cancer is one of the most commonly diagnosed cancer, most 
patients with NSCLC are being diagnose in a late stage and lost the opportunity of surgery. 
Platinum –based regimens in overall survival and quality of life shown meagre improvement. 
Study on single nucleotide polymorphism (SNP) showing significant improvement on detecting 
risk of lung cancer and overall survival by study and by measure and evaluate molecularly defined 
biomarkers. 
Results: 
A total of 335 lung cancer patients, the number of responders (CR or PR) were 100 and non-
responders (PD or SD) were 235. All patients received platinum-based chemotherapy, cisplatin-
based was 153(45.7%) and carboplatin-based was 182(44.3%). age (P-value 0.037), histology 
(0.022) and ECOG (0.033) may be considered statistically significant risk factors on platinum-
based chemotherapy efficacy in all population. The rs31839825 SNP showed a significant 
association with chemotherapy response when considering the additive model (OR=0.67, 
P=0.033). The relationship of the SNP with response to chemotherapy showed significant 
associations with chemotherapy response: for stage I-II in additive (OR=1.89, P=0.017) and 
dominant (OR=2.1, P=0.014) models, for EAC in additive model (OR=0.83, P=0.041), for non-
smoking (OR=0.47, P=0.048), and for cisplatin (OR=0.51, P=0.046) in recessive model. 
Conclusion: 
Results prove that there is a correlation between response and resistance to platinum based 
chemotherapy. It also suggests that there is a connection between resistance to a drug and the 
histology and association between the gene polymorphism and lung cancer risk or chemo 
sensitivity. More studies need to be performed to investigate the potential linking rs3183982 
polymorphism in PDCD6IP encoding protein required for apoptosis with cancer progression and 
prognosis 
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4. INTRODUCTION 
 
4.1.  Pharmacogenetics  
The term pharmacogenetics was officially published by the German physician Friedrich Vogel in 
porphyria [1]. 
In October 1957, an article was published by Journal of the American Medical Association which 
showed the confluence of several scientific developments applied to medicine including the 
emergence of human biochemical genetics, which explained inborn errors of metabolism to be 
caused by enzyme malfunctions due to gene mutations. Two different adverse drug reactions 
shown to be caused by a specific genetic enzyme variant affecting the drug’s metabolism [2].  
The identification of primaquine-induced haemolytic anaemia among African-Americans (later 
shown to be due to glucose-6-phosphate dehydrogenase [G6PD] variant alleles) is another relevant 
scientific discovery in the 1950s [3]. 
One of the most influential discoveries for pharmacogenetics and its potential clinical utility was 
the identification in 1977 of the hepatic cytochrome P450 oxidase that controls debrisoquine and 
sparteine metabolism [4].  Subsequent population and family studies identified specific drug 
metabolism phenotypes and suggested 1959, but unusual drug reactions based on biochemical 
individuality were observed in 1930s. 
This was in results to earlier observations of interindividual variability in phenylthiocarbamide 
taste perception and isolated cases of drug-induced that the “poor metabolism” trait was inherited 
in an autosomal recessive Mendelian fashion. The responsible enzyme, CYP2D6, was purified, the 
corresponding cDNA cloned, and the gene extensively sequenced and is now believed to be 
directly involved in the metabolism of ~25% of all commonly used drugs. More than 80 variant 
CYP2D6 alleles have since been discovered worldwide, many of which encode deficient enzyme 
activity, and these are carefully catalogued by the Human Cytochrome P450 (CYP) Allele 
Nomenclature Committee [5]. 
In the late 1800s, the concept of “personalized medicine” was anticipated by the Canadian 
physician Sir William Osler who noted “the great variability among individuals”, however the 
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final definition has evolved that not only patient’s clinical assessment and family history were 
involved in guiding medical management but also personal genomic information [6]. 
 
Facilitating more effective drug therapy by using pharmacogenetic biomarkers as well as studying 
how genes and the environment interact to cause human disease are major areas of research 
involved in the identification of the genetic basis of common diseases. 
Pharmacogenetics is the study of germline genetic variation resulting in altered absorption, 
distribution, metabolism and excretion associated with the efficacy or toxicity of a drug, or 
affecting drug interaction with the target protein.  Generally, pharmacogenetics has focused 
predominantly on reducing adverse drug reactions, but recently several applications on the area of 
efficacy have been reported. Correct dosage, adherence to medication and treatment schedules, 
avoidance of drug-drug interactions and correct drug choice all have an important role to 
complement pharmacogenetics. 
 
 
4.2. Principles of pharmacogenetics 
Genetic polymorphism can occur when a single genetic trait is expressed in two or more different 
ways in the population. Each one of us have our own unique genetic coding for our body, every 
person reacts differently to a particular dose of a drug. Pharmacogenetics tries to study and 
generalize how people react based on their genetic composition. Use of properties of 
pharmacodynamics and pharmacokinetics in order to study these effects 
 
• A single gene encodes a protein whose function may be relevant to several drugs e.g. a 
drug-metabolising enzyme or transporter. 
• Different variants in the same gene may cause different functional effects, which can result 
in reduced or increased activity, altered binding capacity or absence of the protein [7]. 
• A lot of compounds are being identified with extremely potent in vitro activity but are 
found to be inactive in vivo. They can possess the optimal configuration and conformation 
needed to interact with their target receptor or enzyme, but they do not always have 
physicochemical properties and the best molecular form needed for their delivery to the 
site of action. Here helps, prodrugs that can offer many advantages over parent drugs such 
as increased solubility, enhanced stability, improved bioavailability, reduced side effects, 
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and better selectivity. Many prodrugs have been used successfully in the clinic; examples 
include capecitabine in cancer therapy. Many other factors apart from functional variants 
in genes including patient adherence, co-morbidities, and co-medications can influence the 
metabolism of a drug. [8,9]  
 
4.3.  Cancer  
Cancer is the most important unsolved medico-biological problem in the century. There are many 
cancer research teams investigating numerous genetic factors and complex molecular mechanisms 
underlying in the pathogenesis of neoplasia. Harahan and Weinberg believe that most (and 
probably all) type of cancer share a small number of biochemical, molecular and cellular traits 
called acquired capability. They created a logical science where the complexities of the disease 
will become understandable example rules that govern the transformation of normal human cells 
into malignant cancers. It is a simplification from the teaching of cell biology that virtually all 
mammalian carry similar molecular machinery regulating their proliferation, differentiation and 
death. There are more than 200 different types of cancer so this complexity provoke many 
questions [10].  The authors suggested that cancer cell genotypes is a manifestation of six 
alterations relevant for malignancy: 
• Self-sufficiency in growth signals (cell proliferation, differentation and death). 
 Growth signals (GS) known also as stimulatory signals are required by normal cells to activate 
proliferative state. Tumore cells mimicking normal GS and generate many of their own. One type 
of cells creates mitogenetic growth factors (GFs) in order to stimulate proliferation while cancer 
cells are able to synthesize GF to which they are responsive creating a positive feedback signaling 
loop often termed autocrine stimulation. Selfstimulation tumor cell growth is possible due to the 
fact that they are provided with appropriate surface receptors composed of the extracellular 
portion and the intracellular tyrosine kinase that is divided into two parts catalyst. Overexpression 
platelet- derived growth factor (PDGF) and its receptor occurs in human small cell lung cancer 
[11]. 
• Insensitivity to growth- inhibitory (antigrowth) signals.  
Antigrowth signals can block proliferation by two distinct mechanisms either cell forced out for 
active proliferative cycle into quiescent stage Gₒ (they might change in the future) or cell induced 
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to permanently abandon their proliferative potential by entering into post-mitotic states(associated 
with mature cells that have differentiated).The cancer cell must therefore avoid these signals if it is 
to continue dividing uncontrollably.  At the molecular level, nearly all antigrowth signals are 
funneled through a protein known as the retinoblastoma protein (classified as a tumor suppressor 
protein). A primary function of retinoblastoma is to bind to and inactivate E2F transcription 
factors. These are extremely important proteins that bind to DNA and activate genes which control 
the cell cycle and DNA replication. TGF- β - transforming growth factor beta has many different 
mechanisms for preventing the phosphorylation of retinoblastoma (i.e. for preventing the 
disengagement of the brakes). Therefore, the presence of TGF- β blocks the advancement of the 
cell cycle.  Unfortunatly many cancers can disrupt this pathway either by stoping the  response to 
TGF-beta altogether, by producing less TGF-β receptors on their cell surfaces or producing 
mutated receptors that do not respond to the presence of TGF-β 
•  Evasion of apoptosis. 
The ability of tumor cell population to expand in number is determined not only by the rate of cell 
proliferation but also by the rate of cell attrition. There are two categories of apoptotic machinery 
regulators and effectors. The regulators are responsible for monitoring the interior and exterior 
environment of the cell for conditions of abnormality (DNA damage, signaling imbalance caused 
by the activation of cancer causing genes (oncogenes), lack of an oxygen supply or insufficient 
growth factors. in order to decide whether that cell should live or die.  Apoptosis can occur either 
through an intrinsic pathway, in which signals from within the cell activate the process, or through 
an extrinsic pathway where death signals from outside the cell are received and processed by the 
cell to activate apoptosis. The primary regulators of apoptosis are proteins from the Bcl-2 family 
group and can either be pro-apoptotic(trigger apoptosis when activated) or anti-apoptotic (inhibit 
apoptosis). The anti-apoptotic proteins bind to and inactivate and the pro-apoptotic proteins in a 
healthy cell that does not need to die. The end result is that antigrowth signals, funnelled through 
Retinoblastoma protein into the cell cycle, the absence of the Retinoblastoma protein permits 
persistent cell division (cancer). Mitochondria in response to pro-apoptotic signals relealised 
cytochrome c and bind to a protein known as Apaf-1, resulting in the formation of the 
apoptosome. The apoptosome activate a group of proteins known as caspases (cellular 
executioners). Initiator caspase launch the other caspases in a cascade of irreversible cellular 
protein degradation. P53 is an extremely important protein, it is responsible for detecting DNA 
damage, chromosome abnormalities and arresting the cell cycle to initiate repair; if repair is not 
possible then apoptosis is induced. The most common method is the loss of the apoptosis 
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gatekeeper, the protein P53. More than 50% of all types of human cancers have a mutated or 
missing gene for p53, resulting in a damaged or missing P53 protein. Retinoblastoma and P53, 
that control both cell division and cell death; the result is repeated uncontrolled cell division that 
manifests itself in warts, with strong associations with the development of cancer. Cancer cells can 
also produce excessive amounts of anti-apoptotic proteins or less of the pro-apoptotic. 
• Limitless replicative potential. 
 Most cells in our body can only undergo a limited number of successive cell growth-and-division 
cycles (Hayflick Limit) After undergoing between 40 and 60 divisions, cell growth slows down 
and eventually stops altogether. This state is known as senescence, and it is irreversible; although 
the cell does not grow or divide, it remains alive. Some cells are able to make it past the 
senescence barrier and continue dividing; however these cells then undergo a second phenomenon 
known as crisis, during which the ends of their chromosomes fuse with each other, and the cells all 
die on a massive scale via apoptosis. With every replication of a cell, about 50-100 nucleotides of 
telomeric DNA is lost. This progressive loss eventually causes the telomeres to lose their ability to 
protect the ends of chromosomal DNA. Left unprotected, these exposed ends become damaged. 
The DNA damage response is activated, leading to growth arrest; senescence. When chromosome 
ends fuse with each other, this irreversible damage results in the activation of apoptosis; the cell 
enters crisis, and dies. Cancer cells have therefore not only uncoupled their growth program from 
the signals in their environment, they have also breached the in-built replication limit hard wired 
into the cell by maintain their telomeres. 90% of them do so by increasing the production of a 
telomerase (by adding telomeric DNA to the ends of chromosomes). Most normal cells do not 
divide frequently, these cells show low telomerase activity levels. Many cancer causing proteins 
(oncoproteins) are able to activate the production of telomerase, while many cancer preventing 
proteins (tumor suppressors) such as P53 produce factors that inhibit the production of telomerase. 
The defining feature of a cancer cell is its ability to divide endlessly, without exhaustion, 
generation after generation. They achieve this by destroying the cellular timekeeper, the telomere. 
Immortality comes at a price; the accumulation of damaging mutations only increases with time, 
which is why cancer is primarily a disease of an aging population. The immortalization of cancer 
cells by telomere maintenance therefore represents an essential step in tumour progression. 
• Sustained angiogenesis. 
In a developing embryo or a healing wound, require oxygen and nutrients, as well as a facility to 
remove metabolic wastes and carbon dioxide. The formation of new blood vessels, known as 
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angiogenesis, satisfies these needs. In a similar manner, a growing tumour, an aggregation of 
cancer cells, also requires access to oxygen, nutrients and waste disposal. When the tumour begins 
to starve cancer cells send out signals to the cells of nearby blood vessels, inducing these innocent 
bystanders to grow extensions to form a supply chain and drainage channels.  As a result, these 
rapidly growing tumours have extremely low levels of apoptosis and extremely high levels of cell 
division. In adults, angiogenesis is only switched on during physiological processes such as 
wound healing or menstruation, and then only transiently and regulated extremely carefully while 
in  cancer cells angiogenesis process is switched on all the time. Counterbalancing  positive 
(primary angiogenic growth factor being VEGF (Vascular Endothelial Growth Factor) causes 
endothelial cells to first break through existing blood vessels, then migrate towards the signal 
grow and replicate and form new blood vessels as directed) and negative signals (include the 
prototypical thrombospondin-1 protein, which inhibits the growth and migration of endothelial 
cells. The binding of thrombospondin-1 to endothelial cells triggers the activation of caspases, 
leading to apoptosis of the cell, circulate in the cellular microenvironment surrounding every cell, 
respectively encouraging or blocking angiogenesis. The rapid growth of a tumour results in an 
oxygen delivery problem; cells (hypoxic- activate the hypoxia stress response) found towards the 
inside of the tumour are deprived of an adequate supply of oxygen.  Hypoxia inducible factor 
(HIF) transcription factor, initiating the production of other proteins required to mediate the 
effects of hypoxia. The accumulated HIF transports into the nucleus of the cell where it induces 
the expression of numerous target genes, including VEGF. This increase in VEGF results in 
shifting the balance of angiogenesis inducers and inhibitors, thereby switching on angiogenesis. 
By activating the angiogenic switch, tumours growth endothelial cells.  Angiogenesis in a cancer 
is a perversion of a normal cellular process, a perversion that is an essential requirement for the 
development of cancer. 
• Tissue invasion and metastasis (immune and inflammatory responses , extracellular maxtix 
remodeling, angiogenesis and cell adhesion).  
Primary tumor masses spawn pioneer cells that move out,  effects  adjacent tissues continue  to 
travel  to distant  sites  founding new colonies. Those distant  settlements of tumor cells  cause of 
90%  of human cancer deaths. There are several classes of proteins involved in  invade 
surroundings tissue, include cell- cell adhesion molecules (CAMs). Cell-to-environment  
interactions in cancer involves E-cadherin  expressed on epitherial cells. Adjacent  cells by E-
cadherin  results in  transmission  of antygrowth via  cytoplasmic contacts with β-catenin to  
intracellular signals circuits that include the Lef/ Tcf transcription factor.   Several mechanisms 
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like mutations inactivation of E-cadherin or β-catenin, transcriptional repression, proteolysis of the 
extracelullar cadherin domain cause of E-cadherin function lost  and force expression of E-
cadherin in cultured cancer cells. N-CAM  switch in expression from a highly adhesive isoform to 
poorly adhesive forms in small cell lung cancer, it is an example of  changes in expression of 
CAMs that appear to have a critical function in the processes of invasion and metastasis. 
In figure 3.3.1 several types of protective/controling mechanisms responding to tumour growth are 
shown. As discribes above alterations in genes encoding regulatory proteins of major 
interconnected signalling pathways controlled by p53 that is reported for many tumours. It is very 
important to understand the role of individual genetic background as a factor in deregulation of 
cell proliferation, differentiation and death control. From the figure 3.3.1 that progression- early 
stage of cancer depends on these mechanism. Unfortunately tumours are never detected 
immediately after initiation. Most of the time diagnose is made when malignant progression 
continued, and invasion already started. For this reason researchers in terms of cancer risk 
investigate more and more polymorphisms in genes encoding factors of growth-controlling 
pathways rather than progression modulation. 
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Figure 3.3.1. Stage of tumour development and involved protective and modulating 
mechanisms affected by common gene polymorphisms. 
The regulation of somatic-cell number is a splendid example of homeostasis—the 
sophisticated mechanisms that maintain an organism’s physiology within normal limits. A 
good example of homeostasis is the regulation of somatic cell number. When too many cells 
of a given type are present or when there is a deficiency of cells, cell proliferation or cell 
death accelerates or cell death respectively (figure 3.3.2). When a mutation appears in the 
genes governing those homeostatic mechanisms, the consequences are dramatic: the 
accumulation of multiple mutations accelerating proliferation and blocking cell death in the 
same somatic cell is the underlying cause of cancer [12]. 
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Figure 3.3.2. Overview of the regulation of cell number in normal and cancer cells. 
(a) Proper external cues for normal cell survival and proliferation. (b) Proper external 
cues for normal cell death or inhibition of proliferation. (c) Proper external cues for 
normal cell survival without proliferation. (d) Self-generated survival and 
proliferation signals in cancer cells. 
 
Globally, cancer is one of the top ten leading causes of death. It is estimated that 7.4 
million people died of cancer in 2004 and, if current trends continue, 83.2 million 
more will have died by 2015 [13]. The burden of cancer is increasing in 
economically developing countries as a result of population aging and growth as well 
as, increasingly, an adoption of cancer-associated lifestyle choices including 
smoking, physical inactivity, and ‘‘westernized’’ diets. In 2008 about 12.7 million 
cancer cases  
and 7.6 million cancer deaths are estimated to have occurred in of these, 56% of the 
cases and 64% of the deaths occurred in the economically developing world [14, 15].  
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Annual report in the US estimates that there were 2 million new cases diagnosed and 
750 thousand deaths caused by cancer in 2014 in the US [16].   
 
 
4.4. Lung cancer  
Lung is the leading cancer site in males, comprising 17% of the total new cancer cases and 
23% of the total cancer cases.  
Lung cancer was the most commonly diagnosed cancer as well as the leading cause of cancer 
death in males in 2008 globally.  Among females, it was the fourth most commonly diagnosed 
cancer and the second leading cause of cancer death. Lung cancer accounts for 13% (1.6 
million) of the total cases and 18% (1.4 million) of the deaths in 2008. Despite their lower 
prevalence of smoking (less than 4% adult smokers), Chinese females have higher lung 
cancer rates (21.3 cases per 100,000 females) than those in certain European countries such as 
Germany (16.4) and Italy (11.4), with an adult smoking prevalence of about 20%. The 
relatively high burden of lung cancer in women is thought to reflect indoor air pollution from 
unventilated coal-fuelled stoves and from cooking fumes in China. Other known risk factors 
for lung cancer include exposure to several occupational and environmental carcinogens such 
as asbestos, arsenic, radon, and polycyclic aromatic hydrocarbons. 
The observed variations in lung cancer rates and trends across countries or between males and 
females within each country largely reflect differences in the stage and degree of the tobacco 
epidemic. Smoking accounts for 80% of the worldwide lung cancer burden in males and at 
least 50% of the burden in females. The lung cancer rates are increasing in countries such as 
China and several other countries in Asia and Africa, where the epidemic has been established 
more recently and smoking prevalence continues to either increase or show signs of stability 
[16]. 
 
Page | 19 
 
4.4.1.  Non-small cell lung carcinoma 
Lung cancer consists of two types: non-small cell lung cancer (NSCLC) and small cell lung 
cancer (SCLC). In this work all patients recruited had NSCLC which corresponds to about 80-
90% of lung cancer cases. There are 3 main subtypes of NSCLC. The cells in these subtypes 
differ in size, shape, and chemical make-up when looked at under a microscope. But they are 
grouped together because the approach to treatment and prognosis are often very similar. 
• Adenocarcinoma: About 40% of lung cancers are adenocarcinomas. These cancers 
tend to stain mucin positive as they are derived from the mucus producing glands of 
the lungs. This type of lung cancer occurs mainly in current or former smokers, but it 
is also the most common type of lung cancer seen in non-smokers.  It is more common 
in women than in men, and it is more likely to occur in younger people than other 
types of lung cancer. Adenocarcinomas are highly heterogeneous tumours [17]. 
Adenocarcinomas are usually found in outer parts of the lung. They tend to grow 
slower than other types of lung cancer, and is more likely to be found before it has 
spread outside of the lung. People with a type of adenocarcinoma called 
adenocarcinoma in situ (previously called bronchioloalveolar carcinoma) tend to have 
a better prognosis than those with other types of lung cancer [18]. 
             
            Picture 3.4.1. Squamous carcinoma lung 
 
• Squamous cell (epidermoid) carcinoma: About 25% to 30% of all lung cancers are 
squamous cell carcinomas.  These cancers start in early versions of squamous cells, 
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which are flat cells that line the inside of the airways in the lungs. They are often 
linked to a history of smoking and are more common in men than in women. It tends 
to be found in the middle part of the lung, it often metastasizes to loco regional lymph 
nodes early in its course and generally disseminates outside the thorax somewhat later 
than other major types of lung cancer [19]. 
 
 
Figure 3.4.2 Squamous carcinoma lung- cytology. 
• Large cell (undifferentiated) carcinoma: This type of cancer accounts for about 10% to 
15% of lung cancers. It can appear in any part of the lung.  It tends to grow and spread 
quickly, which can make it harder to treat. A subtype of large cell carcinoma, known 
as large cell neuroendocrine carcinoma, is a fast-growing cancer that is very similar to 
small cell lung cancer [20]. 
• Other subtypes: There are also a few other subtypes of non-small cell lung cancer, 
such as adenosquamous carcinoma and sarcomatoid carcinoma. These are much less 
common. 
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Figure 3.4.3 Pie chart of  types of lung cancer, considering the smoking status. 
The main treatment methods for lung cancer are surgery, radiation, platinum-based doublet 
chemotherapy and tyrosine kinase inhibitor (TKI). Unfortunately most patients are being 
diagnose in a late stage and lost the opportunity of surgery. Platinum –based regimens in 
overall survival and quality of life shown meagre improvement. In advanced NSCLC median 
overall survival is still 10-12 months, but in some molecularly defined subgroups to have 
much better prognosis. Scientist constantly work on improvement in risk of lung cancer and 
overall survival by study single nucleotide polymorphism (SNP) and by measure and evaluate 
molecularly defined biomarkers [21].  
 
4.4.2. Stages of cancer 
If a biopsy shows cancer, more imaging tests are done to find out the stage of the cancer. 
Stage means how big the tumour is and how far it has spread. NSCLC is divided into five 
stages: 
•Stage 0 - the cancer has not spread beyond the inner lining of the lung 
•Stage I - the cancer is small and has not spread to the lymph nodes 
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•Stage II - the cancer has spread to some lymph nodes near the original tumour 
•Stage III - the cancer has spread to nearby tissue or too far away lymph nodes 
•Stage IV - the cancer has spread to other organs of the body, such as the other lung, brain, or 
liver 
 
4.4.3.  Stages, diagnose and spread of Non-Small Cell Lung Cancer 
After lung cancer has been diagnosed, it is important to know the stage in order to plan 
treatment. Some of the tests used to diagnose non-small cell lung cancer are also used to stage 
the disease include: MRI (magnetic resonance imaging), CT scan (CAT scan), PET scan ( to 
find malignant tumour cells), radionuclide bone scan, pulmonary function test (PFT), 
endoscopic ultrasound (EUS), mediastinoscopy (to look at the organs, tissues, and lymph 
nodes between the lungs), anterior mediastinotomy (to look at the organs and tissues between 
the lungs and between the breastbone and heart), lymph node biopsy, bone marrow aspiration 
and biopsy. 
Unfortunately cancer can spread very fast through tissue, the lymph system, and the blood. 
When the primary tumour spread to another part of the body is called metastasis. 
The following stages are used for non-small cell lung cancer (Figure 3.4.3.1): 
• Occult (hidden) stage 
In the occult (hidden) stage, cancer cannot be seen by imaging or bronchoscopy. Cancer cells 
are found in sputum (mucus coughed up from the lungs) or bronchial washing (a sample of 
cells taken from inside the airways that lead to the lung). Cancer may have spread to other 
parts of the body. 
• Stage 0 (carcinoma in situ) 
In stage 0, abnormal cells are found in the lining of the airways. These abnormal cells may 
become cancer and spread into nearby normal tissue. Stage 0 is also called carcinoma in situ.
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Figure 3.4.3.1 Illustrations of stages in Non-Small Cell Lung Cancer Patients 
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Stage I 
• Stage IA: The tumour is in the lung only and is 3 centimetres or smaller. 
• Stage IB: Cancer has not spread to the lymph nodes and there are few more 
possibilities: 
a. The tumour is between 3 and 5 centimetres. 
b. Cancer developed in main bronchus and is at least 2 centimetres below where the 
trachea joins the bronchus. 
c. Cancer attacked to the innermost layer of the membrane that covers the lung. 
d. Part of the lung has collapsed or developed pneumonitis  
Stage II 
• Stage IIA (1) Cancer has spread to lymph nodes on the same side of the chest as the 
tumour. The lymph nodes with cancer are within the lung or near the bronchus. The 
tumour is not larger than 5 centimetres. 
• Stage IIA (2) Cancer has not spread to lymph nodes. The tumour is larger than 5 
centimetres but not larger than 7 centimetres. 
Common option for IIA (1 and 2):  
a. Cancer has spread to the main bronchus and is at least 2 centimetres below where the 
trachea joins the bronchus. 
b. Cancer has spread to the innermost layer of the membrane that covers the lung. 
c. Part of the lung has collapsed or developed pneumonitis (inflammation of the lung) in 
the area where the trachea joins the bronchus 
Stage IIB  
• Stage IIB (1) Cancer has spread to nearby lymph nodes on the same side of the chest 
as the tumour. The lymph nodes with cancer are within the lung or near the bronchus. 
The tumour is larger than 5 centimetres but not larger than 7 centimetres. 
• Stage IIB (2) Cancer has not spread to lymph nodes. The tumour is larger than 7 
centimetres. 
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Common options for Stage II B (1 and 2) 
a. Cancer has spread to the main bronchus (and is less than 2 centimetres below where 
the trachea joins the bronchus), the chest wall, the diaphragm, or the nerve that 
controls the diaphragm. 
b. Cancer has spread to the membrane around the heart or lining the chest wall. 
c. The whole lung has collapsed or developed pneumonitis (inflammation of the lung). 
d. There are one or more separate tumours in the same lobe of the lung. 
Stage III 
Stage IIIA 
• IIIA (1) Cancer has spread to lymph nodes on the same side of the chest as the tumour. 
The lymph nodes with cancer are near the sternum (chest bone) or where the bronchus 
enters the lung.  
• IIIA (2) Cancer has spread to lymph nodes on the same side of the chest as the tumour. 
The lymph nodes with cancer are within the lung or near the bronchus.  
• IIIA (3) Cancer has not spread to the lymph nodes and the tumour may be any size. 
Cancer has spread to any of the following: 
a. Heart. 
b.Major blood vessels that lead to or from the heart. 
Common option for spreading cancer in stage IIIA (1 and 2) 
The tumour may be any size. 
Part of the lung (where the trachea joins the bronchus) or the whole lung may have collapsed 
or developed pneumonitis (inflammation of the lung). 
a. There may be one or more separate tumours in the same lobe of the lung. 
b. Cancer may have spread to any of the following: 
c. Main bronchus, but not the area where the trachea joins the bronchus. 
d. Chest wall. 
e. Diaphragm and the nerve that controls it. 
f. Membrane around the lung or lining the chest wall. 
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g. Membrane around the heart. 
Common option for spreading cancer in stage IIIA (2 and 3) 
a. Trachea. 
b. Esophagus. 
c. Nerve that controls the larynx (voice box). 
d. Sternum (chest bone) or backbone. 
e. Carina (where the trachea joins the bronchi). 
Stage IIIB 
• Stage IIIB (1) Cancer has spread to lymph nodes above the collarbone or to lymph 
nodes on the opposite side of the chest as the tumour. Part of the lung (where the 
trachea joins the bronchus) or the whole lung may have collapsed or developed 
pneumonitis (inflammation of the lung). 
• Stage IIIB (2) Cancer has spread to lymph nodes on the same side of the chest as the 
tumour. The lymph nodes with cancer are near the sternum (chest bone) or where the 
bronchus enters the lung. There may be separate tumours in different lobes of the same 
lung. 
Common other symptoms of stage III B (1 and 2) 
a. The tumour may be any size. 
b. There may be one or more separate tumours in any of the lobes of the lung with 
cancer. 
c. Cancer may have spread to any of the following: 
d. Main bronchus. 
e. Chest wall. 
f. Diaphragm and the nerve that controls it. 
g. Membrane around the lung or lining the chest wall. 
h. Heart or the membrane around it. 
i. Major blood vessels that lead to or from the heart. 
j. Trachea. 
k. Esophagus. 
l. Nerve that controls the larynx (voice box). 
m. Sternum (chest bone) or backbone. 
Page | 28 
 
n. Carina (where the trachea joins the bronchi) 
 
• Stage IV 
In stage IV, the tumour may be any size and cancer may have spread to lymph nodes. 
Unfortunately there might be other option like: 
• There are one or more tumors in both lungs. 
• Cancer is found in fluid around the lungs or the heart. 
• Cancer has spread to other parts of the body, such as the brain, liver, adrenal 
glands, kidneys, or bone [22]. 
 
 
4.5. Platinum- based chemotherapy 
Surgery is the mainstay of treatment for early stage and localised disease (StageⅠand Ⅱ and 
selected ⅢA). Following lung resection for NSCLC five year survival rates areⅠA-73%Ⅰ, 
B-54%, ⅡA-48%, ⅡB-38%, ⅢA-25% [6]. The majority of patients have advanced disease at 
the time of diagnosis and therefore are not surgical candidates, in the United Kingdom only 
14% of patients diagnosed go on to have surgical resection. In those patients that are surgical 
candidates, more than 50% will develop a recurrence. Adjuvant chemotherapy has been used 
with limited success to decrease the recurrence rates but this has only yielded a survival 
benefit of 5%-15%. Due to advanced disease or recurrence following resection, different 
chemotherapy forms were proposed for patients. In the first line setting the most effective is 
platinum- based combination. 
Unfortunately, in a recent trial of platinum combination therapies in advanced NSCLC, only 
30% of patients showed objective disease response and a significant proportion suffered toxic 
side-effects such as neutropenia (27%), anaemia (10%), thrombocytopenia (13%), alopecia 
(21%) and nausea (4%). During the trial, deaths due to study drug toxicity were registered. 
This demonstrates the major problem of drug resistance in NSCLC to standard platinum based 
therapies and the associated toxicities [23]. 
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Survival has been improved when cisplatin is given postoperatively to those with stage I1 or 
IIIA disease, with radiotherapy in stage IIIB disease, or alone in stage IV disease. Cisplatin is 
one of the most active agents in NSCLC with an overall response rate of about 20%. More 
recently it has been shown that various combinations of cisplatin or carboplatin, in particular 
the combination of cisplatin and paclitaxel, but also combinations with gemcitabine, 
docetaxel, navelbine, and irinotecan can also prolong survival in NSCLC [24]. 
Platinum based therapy refers to a specific class of cytotoxic chemotherapy drugs that are 
derived from the element platinum. The antitumor properties of platinum-containing drugs are 
attributable in large measure to the kinetics of their ligand displacement reactions.  Their 
primary target is believed to be nitrogen donor atoms in the bases of DNA. The bonds formed 
between the metal ion and these atoms must be sufficiently long-lived to interfere with the 
process of cell division, or to trigger the intracellular mechanisms that recognize irreparable 
damage to a cell. Bonds between the base nitrogen atoms and platinum clearly fulfil this 
requirement.  
Cisplatin (cis-diamminedichloroplatinum Ⅱ) is a relatively unreactive molecule, it does not 
react directly with any other molecules present in biological systems that will bind to the 
platinum through nitrogen or oxygen donor groups,𝑁7 position of guanine and adenine in 
intact DNA.  Hydrolysis of cisplatin is usually considered to be a necessary prelude to its 
reaction with DNA. The aqua complexes also react more readily than cisplatin with molecules 
present in vivo other than target DNA. They therefore are involved in reactions that lead to 
toxicity. Cisplatin is usually given at a dosage of 50-120 mg m-² per cycle. 
Carboplatin is less toxic than cisplatin but also has antitumor activity on an equal-dose basis. 
These properties are correlated with its much lower tendency to undergo hydrolysis reactions-
indeed, the rate of hydrolysis is negligibly slow under physiological conditions. Carboplatin 
does react directly with guanosine monophosphate, but only at slow rates. The dose is usually 
customised for each patient using the area under the concentration-time curve (AUC 200-
350mg m-²) and renal function of the patient, because this drug undergoes extensive renal 
excretion. Cisplatin and carboplatin do react directly with sulphur-containing ligands (e.g., 
methionine, cysteine) without the need for prior hydrolysis [25]. Both agents are usually given 
every 3-4 weeks, for 3-6 cycles. However, because of the toxicity of cisplatin, less toxic 
platinum alternatives have been discover. Two drug combination cisplatin plus paclitaxel, 
vinorelbin, gemcitabine or decetaxel and, carboplatin plus paclitaxel were compared with 
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monotherapy in terms of response rate, survival rate, efficiency and toxicity.  There were not 
significant different between monotherapy and combination drugs between platinum agent.  
When compared gemcitabine (non-platinum agent) with gemcitabine plus cisplatin showed a 
significant advantage in response rate, survival distribution and longer time to progression 
[26]. 
 
4.5.1. Gene polymorphisms affecting outcome of cancer therapy 
(cancer pharmacogenetics) 
Drug-related toxicity depends on the genotype of no tumour tissue which means that inherited 
polymorphisms will have a key role with respect to toxicity, a crucial dose-limiting factor in 
most cancer chemotherapy regimens. 
Many of the variant forms of drug-metabolizing enzymes show small deviation from wild-
type enzyme activity. It is possible that the combination of several polymorphisms in 
components of a ‘biological’ pathway or ‘pharmacological’ pathway might significantly 
influence therapeutic response (significant changes in the ability to metabolize drugs)  
It is well understood the importance of gene variants encoding enzymes of the metabolic 
pathways interacting with anticancer drugs. 
The main target of assessing genetic background in cancer patients (mostly those with 
advanced tumours) under-going cytotoxic chemotherapy or radiotherapy is to find out 
information allowing to select therapeutic strategies rendering maximal damage to target 
tumour cells with minimal side effects and eventually leading to improved survival and 
comfort of life. Polymorphic genes mainly being research in problem in cancer therapy: 
general response to anticancer drugs (toxicity and its modulation) and modulation of specific 
responses (sensitivity/resistance) of tumours to anticancer drugs defining the efficacy of 
therapeutic procedures. 
Recently developed ‘-genomic approaches’, which use microarray technology to describe 
gene or protein expression in its entirety will certainly be useful in refining cancer diagnoses 
and, in turn, predicting tumour response to specific drugs [27]. 
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4.5.2. Platinum Resistance 
Platinum agents are used as an effective and successful chemotherapeutics, unfortunately 
majority of patients develop drug resistance and metastases.  Recent study provide novel 
target for therapy. There are several factors involved in the drug resistance development, 
including gene mutations, genome alterations and epigenetic changes.  
 
It has become a great challenge in response of lung cancer patients the development of innate 
ad acquired resistance.  Cisplatin is taken up through a combination of passive diffusion and 
active transport via membrane bound transporters such as Na+, K(+)-ATPase1 and several 
copper transporters such as copper transporter receptor 1 (CTR1). It have been development 
there is a correlation between cisplatin resistance and expression level of these transporters. 
To yield an active compound of cisplatin by series of aquation reactions, with one or both 
chlorides being replaced by a water inside the cell. 
 
Activated cisplatin is a highly reactive compound, capable of binding DNA, RNA, proteins 
and membrane phospholipids. The primary cytotoxic mechanism of cisplatin is the formation 
of DNA adducts. The majority of adducts formed by cisplatin cross links between adjacent 
purine bases represent the vast and the 1, 2-intrastrand. DNA protein cross links with consist 
of 1, 3-intrastrand. Formed adducts changed structure of the DNA molecule leading to steric 
changes in the DNA helix. Changes in DNA structure are recognised and repaired by complex 
network of DNA repair pathways, terminating in the destruction of the cell. DNA repair 
mechanisms show differences in tumour cells to normal counterparts, and some of them may 
also be acquired, the role of this DNA repairs in cisplatin resistance tumours is investigating. 
Tumour cell lines with acquired resistance to cisplatin have been shown to have an increased 
capacity for removing cisplatin- induced DNA lesions in comparison to their cisplatin 
sensitive counterparts. The tumour suppressor gene, p53 is very important in damage 
recognition and initiation of repair and binds with a high affinity to palatinate DNA. The 
studies show that loss of p53 confer cisplatin resistance in ovarian cancer, whilst restoration 
of wild type p53 via adenoviral transfection can restore sensitivity and promote apoptosis. 
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Researchers have demonstrated interactions between p53 signalling and cisplatin in lung 
cancer cells [28]. 
Cisplatin resistant phenotype observed in the different cancer types (most in lung cancer) by 
contribution of multiple mechanisms and pathways in tumour cells (figure 3.5.2.1). These 
include, decreased intracellular drug accumulation due to alterations in expression of 
receptors such as CTR1 and the copper-transporting P-type adenosine triphosphates, ATP7A 
and ATP7B (A), increased inactivation of cisplatin by intracellular thiol-containing molecules 
such as glutathione (GSH) and metallothionein (B), increased DNA repair due the enhanced 
capacity of tumour cells to remove cisplatin-induced DNA lesions (C), suppressed caspase 
activity and reduced apoptotic response as a result of alterations in pro-apoptotic factors such 
as Bax, Bak and apoptosis inhibitors such as Bcl-2 (D). 
 
Figure 3.5.2.1 Mechanism of cisplatin resistance in tumour cells. 
Inhibitors of histone deacetylases HDAC is been recently propose for treatment NSCLC 
patients. Performed study was to examine the capability of the pan-histone deacetylase 
inhibitor SAHA and of ST35595, a novel hydroxamate-based compound, to interfere with the 
proliferative and invasive potential of NSCLC cells. The results confirmed an improvement in 
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terms of pro-aprotic, anti-invasive activity in vitro an antimetastatic activity in vivo in 
ST35595 over SAHA [29].  
 
4.6.  SNP (Single Nucleotide Polymorphism) 
The term polymorphism has been defined in 1986 as a ‘Mendelian trait that exists in the 
population in at least two phenotypes, neither of which occurs at a frequency of less than 1%’ 
[30]. 
It is generally believed that the genomes between two randomly selected individuals contain 
approximately 0.1% difference or variation. This variation is called ‘‘polymorphism’’ and it 
arises because of mutations. The simplest form of DNA variation among individuals is the 
substitution of one single nucleotide for another. This type of change is called ‘‘single 
nucleotide polymorphism’’ (SNP) and it is found to be more common than other types of 
polymorphisms. It is estimated that SNPs occur at a frequency of approximately one in 1,000 
base pairs (bp) throughout the genome and more than three million SNPs have been charted 
so far. These simple changes are believed to be stable and not deleterious to organisms.  
According to a published report, 50% of SNPs occur in noncoding regions, 25% lead to 
missense mutations, and the remaining 25% are silent mutations. No synonymous SNPs 
(altering amino acids) may often produce disease and therefore may be subjected to natural 
selection. SNPs can be observed between individuals in a population, and may, for example, 
influence promoter activity (gene expression), messenger RNA (mRNA) conformation 
(stability), and translational efficiency. Therefore, they may be responsible for the 
susceptibility of an individual to many common diseases, therapeutic drug metabolism, and 
genome evolution. They may also play a direct role with or without other factors in the 
phenotypic expression of diseases or traits such as tallness, curly hair, and individuality. In 
recent years, application of clinic genetic knowledge has revolutionized our ability to 
understand the effects of nucleotide substitutions and genetic basis of several complex and 
common disorders [31]. 
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4.7.  Gene 
 The man is a carrier of an average of 10-20 genes that predispose to serious illness. However, 
this does not mean that you have to get sick.  
 Nearly all cancers are due to gene, because before the disease develops, it must result in 
damage to a particular gene. Genetic defect that makes the cells begin to multiply 
uncontrollably and do not start the development of a restraining mechanism. This does not 
mean, however, that bad genes can be only in the genetic material inherited from the 
ancestors. Sometimes they are damaged by e.g. Smoking or inhalation of toxic fumes (lung 
cancer), or too frequent eating red meat (colorectal cancer). The risk in people under 30 years 
is 0.5%. Then - for 65 years - it increases to 12%, and even old age reaches 23%. The so-
called lifetime risk of developing cancer in all people, irrespective of the family burden is 
assessed at 33%. In contrast, hereditary conditions can speak in approx. 5% of all cancers. 
In inherited cancers involving oncogenes, tumour suppressor genes and the genes responsible 
for the repair of DNA damage. Oncogenes cause uncontrolled division and proliferation of 
cells. It have been described for more than 50 of such genes. They arise from mutations of 
proto-oncogenes, or normal genes, which have each cell. Suppressor genes supervise the 
growth and cell division (not dangerous in normal cell). Only they damage due to the 
mutation causes impairment of their function, and it promotes the formation of cancer. The 
genes responsible for reconstruction repair of damaged DNA, e.g. under the influence of 
radiation. When they are defective, mutated genes, which can lead to cancer development 
[32]. 
 
4.7.1.  PDCD6IP (The programmed cell death 6 interacting protein) 
Programmed cell death (PCD) is a physiologically regulated cell type-specific deletion that 
takes place during various developmental stages of multicellular organisms and is essential 
for the establishment and the maintenance of cellular homeostasis. PCD occurs by apoptosis, 
which refers to the morphological changes that can be observed in cells undergoing PCD. 
These include plasma membrane blabbing, cell shrinkage, chromatin condensation, and DNA 
degradation. The process eventually culminates with the fragmentation of the cells into 
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apoptotic bodies that, in vivo, are rapidly phagocytized by the surrounding cells. Programmed 
cell death has been recognized as an important terminal pathway for cells of multicellular 
organisms, and is involved in a variety of biological events that include morphogenesis, 
maintenance of tissue homeostasis, and elimination of harmful cells [33]. 
This gene encodes a protein that functions within the endosomal sorting complex required for 
transport ESCRT pathway in the abscission stage of cytokinesis, in intraluminal endosomal 
vesicle formation, and in enveloped virus budding. Previous studies have shown that over-
expression of this protein can block apoptosis. Apoptosis play a very important role in cancer 
treatment and in carcinogenesis (describe before). Some kind of damage trigger a series of 
biochemical events, leading to characteristic cell morphology and death. In addition, the 
product of this gene binds to the product of the programmed cell death 6 (PDCD6) gene, a 
protein required for apoptosis, in a calcium-dependent manner. This gene product also binds 
to endophilins, proteins that regulate membrane shape during endocytosis [34]. 
 
Overexpression of this gene product and endophilins result in cytoplasmic vacuolization, 
which may be partly responsible for the protection against cell death. Several alternatively 
spliced transcript variants encoding different isoforms have been found for this gene [35]. 
Dysfunction in an important terminal pathway leads to various cancers in humans. The 
PDCD6IP gene is a plausible cancer susceptibility gene. The localisation of this gene is in 
chromosome 3p22 harbouring several sequence variations in the promoter region. mRNA 
levels of target genes may be affected by genetic variations in the promoter region by altering 
transcription factor (TF) binding sites. A polymorphism (rs28381975) was found in the 
promoter region of PDCD6IP, which could disrupt the binding patterns of the c-rel 
transcription factor. C-rel is a key nuclear factor-kappaB (NF-kB) subunit that plays an 
important role in cell development, proliferation, differentiation, and protection against 
apoptosis. In the study on rs28381975 it was hypothesized that the function of the gene might 
be affecting the bindings of speciﬁc TFs, thus involved in Hepatocellular Carcinoma HCC 
tumorigenesis [36]. 
In this work we hypothesized that this reactions maybe be involved in NSCLC tumorigenesis 
and the association between rs3183982 and the Platinum based chemotherapy in a Chinese 
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population. It is believed that understanding connections between SNP and response rate and 
drug resistant are very important for future improvement of a treatment.  
The ESCRT pathway is a key mediator of multivesicular body MVB biogenesis but also plays 
critical roles in retroviral budding, cytokinesis abscission, receptor down-regulation, and other 
normal and pathological processes. The ESCRT components are conserved in all five major 
subgroups of eukaryotes. Studies shown growing number of links identified between ESCRT-
mediated protein sorting in the MVB (multivesicular body) pathway and various human 
diseases. MVB deliver cargo destined for degradation to the vacuole or lysosome and plays an 
important role in modulating the amplitude and kinetics of the signalling pathways they 
activate and thus the maintenance of normal cellular homoeostasis.  
The endocytic down-regulation of numerous signalling receptors such as the EGFR 
(epidermal growth factor receptor) plays an important role in modulating the amplitude and 
kinetics of the signalling pathways they activate and thus the maintenance of normal cellular 
homoeostasis. EGFR is one of the best-studied receptor tyrosine kinases RTKs, and its 
excessive signalling is associated with the development of a variety of human cancers, 
including mammary carcinomas, squamous carcinomas and glioblastomas, as well as other 
malignant diseases. The MVB pathway terminates receptor signalling via lysosomal 
degradation of the receptor, and thus plays an important role in modulating the amplitude and 
kinetics of various signalling pathways from activated receptors [37]. 
 
4.8. Polymerase chain reaction (PCR)  
Among the molecular biology techniques most commonly used in biotechnological research 
aimed to analyze the state of the environment concerned, there may be mentioned: 
• polymerase chain reaction (PCR), 
• gel electrophoresis and its variants, 
• cloning 
• DNA fragments, 
• DNA sequencing 
• Southern blot hybridization, 
• Northern blot hybridization, 
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• in situ hybridization, FISH, 
• GFP protein, 
• DNA microarrays. 
DNA Polymerase Chain Reaction, allows to quickly replicate the nucleic acid segment. 
Although this is very sensitive and efficient, and thanks to its simplicity regarded today as the 
most important tool in molecular biology. Within a few hours may be amplified fragments of 
the starting DNA106 − 109. Before conducting the PCR reaction mixture need to be prepared 
consisting of: the material for amplification, which is called the matrix DNA, primer, 
deoxynucleotides (deoxynucleoside triphosphates dNTPs), thermostable DNA polymerase 
enzyme and buffer. The primers are DNA fragments that are complementary to sequences 
flanking the DNA segment searched. Most primers selected on the basis of the data-connected 
resident in the literature or are constructed based on the sequence available in the gene bank. 
The reaction mixture is periodically (25-40 cycles), heated to a time-dependent temperature 
phase of the cycle. 
 The main steps of the reaction are depicted in figure 3.8.1: 
• Denaturation of DNA molecules 
• Primer binding (annealing ) 
• DNA chain elongation ( extension ) 
These steps are repeated cyclically, resulting in exponential growth of the reaction product 
(reaction product of each template in the next cycle of PCR). 
When denatured by the high temperature DNA is interleaved to a single strand, which in the 
next step hybridize with the primer pair. Then DNA polymerase on each rebuilding missing 
strand complementary DNA segment, starting from its 3 '. Joining repeated in each reaction 
cycle and consequently receive the amplified fragment located between the primers. Each of 
the stages of the cycle has a different temperature, therefore, the PCR reaction is performed in 
a device called a thermal cycler, wherein the temperature change occurs tens of degrees in a 
few seconds. During the first cycle of each single stranded DNA segment produced another 
piece, so that after the first cycle, the number of fragments is doubled, in a further amount of 
DNA is four times greater and so on. 
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The most important advantage of PCR is the possibility of obtaining multiple copies of genes 
fragments with a small amount of genetic material. PCR products are the basis for further 
analysis and electrophoretic techniques for sequencing, which in the case of environmental 
samples, where we are dealing with a mixture of organisms, must be preceded by cloning. 
It should also be noted that the use of PCR to environmental samples may be associated with 
obstacles resulting from the presence of inhibitors which may cause weakening or complete 
inhibition of the amplification reaction. Inhibitors can be inorganic and organic compounds of 
different origin (e.g. Polysaccharides, urea or humic acids) [38]. 
 
There are at least a few modifications to the PCR, offering new opportunities for research 
below few listed: 
• "Multiplex PCR" PCR Real-time PCR 
• PT-PCR 
• PFGE 
• DGGE / TGGE 
• Horizontal agar 
• Polyacrylamide 
• SDS-PAGE 
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Picture 3.8.1. Illustration of all PCR steeps. 
 
4.8.1. Primers 
The nucleotide sequence of the primers is complementary to the initial portion of the DNA 
strand amplified (forward) and in accordance with amplified propagated terminal fragment of 
the DNA strand (reverse). The primers usually have a length of 15-25 nucleotides, it is 
important that their nucleotide sequence is unique, i.e. not repeated in the test genome. The 
primers should contain 40-60 % G and C nucleotides, and should not contain inverted repeats. 
Melting point (Tm) of the double stranded molecule formed by the two primers 
should be similar (the difference Tm < 5 ° C), primer terminal nucleotides must be G or C, but 
not more than one. The primers should not be complementary to one another  
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(max. 3 consecutive nucleotides can be complementary), or contain stretches of purines 
or pyrimidines [39]. 
 
 
4.8.2. PCR-RFLP (Restriction Fragment Length Polymorphism) 
PCR-restriction fragment length polymorphism (RFLP)-based analysis is a popular technique 
for genotyping.  
 
RELP is a fragment of DNA of predictable size resulting from digestion (cutting) of a strand 
of DNA by a given restriction enzyme. DNA sequence alterations (mutations) that destroy or 
create the sites at which a restriction enzyme cuts DNA change the size (and number) of DNA 
fragments resulting from digestion by a given restriction enzyme. 
 The technique exploits that SNPs, MNPs and microindels often are associated with the 
creation or abolishment of a restriction enzyme recognition site. The first step in a PCR-RFLP 
analysis is amplification of a fragment containing the variation. This is followed by treatment 
of the amplified fragment with an appropriate restriction enzyme. Since the presence or 
absence of the restriction enzyme recognition site results in the formation of restriction 
fragments of different sizes. The length of DNA fragments produced after treatment with a 
restriction enzyme to DNA is determined on the basis of electrophoretic separation in agarose 
gels in the presence of the size markers. 
 
The main adventure is inexpensive. It is Easy to design and there are no requirements for 
expensive instruments and extensive training of laboratory staff. PCR-RELP is applicable to 
analysis of single nucleotide polymorphisms as well as microindels. With all adventures 
always comes dis adventures includes: relatively large amounts of hand-on-time, long time to 
complete the analysis and it is not suitable for high-throughput analysis. Requires that a 
variation generates or abolishes a restriction enzyme (which can be expensive) recognition 
site. Moreover, since PCR-RFLP consists of several steps including an electrophoretic 
separation step, it is relatively time-consuming. Exact genotyping cannot be achieved in the 
event that there is more than one nucleotide variation in a restriction enzyme recognition site 
[40, 41]. 
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4.8.3. Real-time PCR) 
The reaction Real-time PCR amplification reaction of DNA, the quantity of which is 
monitored during the course of the reaction due to the presence in the reaction mixture of dyes 
or fluorescent probes. Dyes connecting with the nucleic acid emit a fluorescent signal 
proportional to the quantity of DNA. The advantages of this technique include high sensitivity 
and speed of execution. Its use allows to determine the relative and absolute amount of the 
matrix, measuring the level of gene expression, to determine gene copy number and to 
distinguish alleles. 
 
4.9. DNA electrophoresis 
Electrophoresis is the process of moving charged molecules in solution by applying an 
electric field across the solution.  Often classified according to the presence or absence of a 
solid supporting medium or matrix through which the charged molecules move in the 
electrophoretic system.  
All types of electrophoresis basic are governed by the principles illustrated by Equation: Mobility of a molecule=(applied voltage)×(net charge on the molecule)(𝑓𝑟𝑖𝑐𝑡𝑖𝑜𝑛 𝑜𝑓 𝑡ℎ𝑒 𝑚𝑜𝑙𝑒𝑐𝑢𝑙𝑒)  
The mobility (rate of migration), of a molecule increases with increased applied voltage and 
increased net charge on the molecule.  Most electrophoretic systems employ an equal and 
constant voltage on all of the cross-sectional areas of the paper strips, gels, or solutions 
employed in the electrophoretic separation. These electric fields are best defined in terms of 
volts per linear centimeter. Ohm’s law (V = IR) dictates that voltage (V) is a function of 
current (I) and resistance (R). The nature of the electrophoresis apparatus and buffer 
composition dictates the resistance in the system. Current is often used to define the voltage 
requirements of an electrophoretic separation. The resistance of the system is important 
because it will determine the amount of heat generated during electrophoresis. Since 
electrophoretic mobility is also a function of temperature, heating of the separation matrix 
must be controlled. 
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 The friction experienced by molecules during electrophoretic migration reflects both 
molecular size and molecular shape. If the electrophoresis is carried out in a medium that 
offers significant barriers to the movement of macromolecules through it (as is the case with 
polyacrylamide and agarose, two very commonly used systems), molecular size may prove to 
be the most important determinant of mobility. If the charge to mass ratio on the 
macromolecules being separated is approximately equal (as in several of the cases discussed 
below), molecular size becomes the sole determinant of electrophoretic mobility [42].  
Several methods have been developed, based on the use of various physical phenomena for 
separation of macromolecules, due to their variable characteristics. These methods have 
become the most popular techniques of electrophoretic techniques. These techniques achieve 
unmatched levels of resolution, and combined with immunostaining techniques, also an 
unprecedented level of selectivity. Speed of movement of electrically charged 
macromolecules is dependent on its charge, size, shape, motion, and environment resistance. 
Based on these properties, a quick separation cam be made of various macromolecules using a 
relatively simple apparatus and with relatively low cost. The main areas of application of 
electrophoresis are: biochemistry of proteins and nucleic acids, molecular biology, 
pharmacology, forensic medicine, veterinary medicine, medical diagnostics. It should also be 
noted that the use of electrophoretic techniques enabled us to obtain the complete sequence of 
human DNA in the recently ended genomics project. All commonly used methods in the final 
stage of DNA sequencing technology are based on electrophoresis. Agarose is mainly used to 
separate larger macromolecules such as nucleic acids whereas a polyacrylamide gel may be 
used to separate nucleic acids or proteins [43]. 
Agarose is a linear polymer composed of alternately arranged residues of D-and L-galactose 
linked by -α (1-3) - α(14) glyosidic bonds. Approx. 800 galactose residues creates a single 
string. It is isolated from algae. Agarose in commercial form is a white or slightly yellow 
powder. Dissolves very readily in boiling water and remains in a liquid state up to a 
temperature of about 40°C. Below this temperature solidifies in the form of a porous gel. 
After solidification remains in this form, even at elevated temperatures of up to several tens 
°C. Pore size can be adjusted using different agarose concentrations. The pore size and 
sieving characteristics of a gel are determined by adjusting the concentration of agarose in the 
gel. The higher the concentration, the smaller the pore size.  Usually agarose gels are prepared 
at concentrations in the range of 0, 4-4, and 0% and are used in a horizontal electrophoresis 
apparatus [44]. 
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Picture 3.9.1. Horizontal electrophoresis. 
 
 
4.10. Data analysis 
 
4.10.1. The Hardy–Weinberg equilibrium 
An individual’s genotype is the combination of alleles found in that individual at a given 
genetic locus. If there are two alleles in a population at locus A (A and a), then the possible 
genotypes in that population are AA, Aa, and aa. Individuals with genotypes AA and aa are 
homozygotes (i.e., they have two copies of the same allele). Individuals with genotype Aa are 
heterozygotes (i.e., they have two different alleles at the A locus). If the heterozygote is 
phenotypically identical to one of the homozygotes, the allele found in that homozygote is 
said to be dominant, and the allele found in the other homozygote is recessive. 
Attendance genes (alleles) - incidence 
P (A) = p = 2∗𝐴𝐴+𝐴𝑎
2∗(𝐴𝐴+𝐴𝑎+𝑎𝑎) 
P (a) = q = 2∗𝑎𝑎+𝐴𝑎
2∗(𝐴𝐴+𝐴𝑎+𝑎𝑎) 
P ( A) + P (s ) = p + q = 1 
attendance genotypes - the incidence  
P ( AA) = AA / ( AA + Aa + aa ) 
P ( Aa ) = Aa / ( AA + Aa + aa )  
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P ( aa ) = aa / ( AA + Aa + aa ) 
P ( AA) + P ( Aa ) + P ( aa ) = 1 
 
LAW Hardy-Weinberg  
Randomly reproduce infinitely large population (there is no genetic drift), in which there is no 
selection, mutation and migration, frequencies of alleles and genotypes are fixed in 
subsequent generations. 
 generation 1 : P ( A) = p                    P (a) = q  
generation 2: P (A) = p                       P (a) = q  
generation n : P (A) = p                      P (a) = q  
Balance genetic: In such a population there is a constant relationship between turnout alleles 
and attendance genotypes,  
p + q = 1  
(p + q) 2 = 1  
p2 + 2pq + q2 = 1 
 P ( AA) = p²                P ( AA) = 2pq              P ( aa ) = q²P 
 (AA ), P (AA ), P ( aa) - the value actually observed in the population ( observed )  
 P² , 2pq , q² - expected values, theoretical , calculated in accordance with the Hardy - 
Weinberg equilibrium (expected) 
Verifying the state of genetic balance in a population means determining if the studied 
population is in equilibrium, i.e. if the number of genotypes observed is consistent with the 
expected number. Since at small deviations it is difficult to conclude whether such 
compliance occurs, the comparison includes conducting a statistical test such as χ2 . 
H0 ( null hypothesis ) : 
In equilibrium population Hardy - Weinberg , i.e. pairing occurs in the random population , 
lack of selection, mutation , migration 
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H0 : P ( AA) = p²     and         P ( Aa ) = 2pq     and              P ( aa) = q² 
H1 ( alternative hypothesis ) : 
population is not in equilibrium Hardy - Weinberg ,i.e. in the population there is random 
mating and / or there are selection , mutation , migration 
H1: P ( AA) ≠ p²     or          P ( Aa ) ≠ 2pq        or                 P ( aa ) ≠ q² 
T (test ) = χ2 = Σ [( Obs - Exp ) 2 / Exp ] 
where: 
• Operation ( Observed ) - the number of observed individuals of a certain phenotype 
• Exp ( expected) - the expected number of individuals of a certain phenotype 
• sum ( Σ ) will contain three components - respectively for the three genotypes at each gene 
locus of the test (AA , Aa , aa) . 
• the calculated value T is compared with the value read from the array TMAX 
χ 2 test for the appropriate number of degrees of freedom and predetermined 
probability ( confidence level) of the rejection or acceptance hypothesis of zero). 
• generally assumed probability (confidence level ) α = 0.95 ; 0.99 or 0, 999 corresponds to 
the so-called significance level P = 0.05 ;0.01 ; 0,001, respectively. 
• The number of degrees of freedom associated with the size of χ 2 is equal to the number of 
data classes [45, 46]. 
It is important to recognize that the Hardy-Weinberg equilibrium is a neutral equilibrium, 
which means that a population perturbed from its Hardy-Weinberg genotype frequencies will 
indeed reach equilibrium after a single generation of random mating (if it conforms to the 
other assumptions of the theorem), but it will be a new equilibrium if allele frequencies have 
changed. This property distinguishes a neutral equilibrium from a stable equilibrium, in which 
a perturbed system returns to the same equilibrium state. It makes sense that the Hardy-
Weinberg equilibrium is not stable, since a change from the equilibrium genotype frequencies 
will generally be associated with a change in allele frequencies (p and q), which will in turn 
lead to new values of p2, 2pq and q2. Thereafter, a population that meets Hardy-Weinberg 
assumptions will remain at the new equilibrium until perturbed again. 
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4.10.2. Minor allele frequency 
Global minor allele frequency (MAF):  dbSNP is reporting the minor allele frequency for 
each included in a default global population. The rs number is an accession number used by 
researchers and databases to refer to specific SNPs. It stands for Reference SNP cluster ID. 
Since this is being provided to distinguish common polymorphism from rare variants, the 
MAF is actually the second most frequent allele value. In other words, if there are 3 alleles, 
with frequencies of 0.50, 0.49, and 0.01, the MAF will be reported as 0.49. The current 
default global population is 1000Genome phase 1 genotype data from 1094 worldwide 
individuals [47]. 
 
4.10.3.  SPSS- Binary Logistic Regression 
The software name stands for Statistical Package for the Social Sciences. (Brand, maker, etc.) 
Logistic regression is used to predict a categorical (usually dichotomous) variable from a set 
of predictor variables.  With a categorical dependent variable, discriminant function analysis 
is usually employed if all of the predictors are continuous and nicely distributed; logic 
analysis is usually employed if all of the predictors are categorical; and logistic regression is 
often chosen if the predictor variables are a mix of continuous and categorical variables 
and/or if they are not well distributed (logistic regression makes no assumptions about the 
distributions of the predictor variables).  Logistic regression has been especially popular with 
medical research in which the dependent variable is whether or not a patient has a disease.  
For a logistic regression, the predicted dependent variable is a function of the probability that 
a particular subject will be in one of the categories (for example, the probability that Suzie 
Cue has the disease, given her set of scores on the predictor variables) [48]. 
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4.10.4. Stratification  
In statistics, stratified sampling is a method of sampling from a population. When sub-
populations vary considerably, it is advantageous to sample each subpopulation (stratum) 
independently. Stratification is the process of grouping members of the population into 
relatively homogeneous subgroups before sampling. The strata should be mutually exclusive: 
every element in the population must be assigned to only one stratum. The strata should also 
be collectively exhaustive: no population element can be excluded. Then random or 
systematic sampling is applied within each stratum. This often improves the 
representativeness of the sample by reducing sampling error. It can produce a weighted mean 
that has less variability than the arithmetic mean of a simple random sample of the population 
[49]. 
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5. Objective 
The aim of this work was to investigate the influence of rs3183982 gene polymorphisms in 
the PDCD6IP gene on the platinum-based chemotherapy response in Chinese non-small cell 
lung cancer patients. The research was focused on reaction in cells that are important in 
NSCLC development, as well as the fundamentals resistant to platinum based chemotherapy. 
Main focus: 
1. Investigating the SNP in the PDCD6IP  
2. Study the process of formating canncer to understand the correlation between reaction 
in cells and the chances by overexprsion of some proteing 
3. Research meaning of platinum resistance and connection to the poor response to group 
of patients.  
4. Try to find answers about genetic markers with lung cancer risk, ways of treatment, 
early diagnose. 
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6. MATERIALS AND METHODS 
 
6.1. Ethics approval 
The clinical research was registered on the Chinese Clinical Trial Registry. The study 
protocol was approved by the Ethics Committee of Xiangya School of Medicine, Central 
South University, Changsha, China. Prior to the study, all patients provided written informed 
consent in compliance with the code of ethics of the World Medical Association (Declaration 
of Helsinki). 
In total, 335 Chinese lung cancer (non-small cell lung carcinoma) patients were recruited 
from November 2011 to May 2013 at Xiangya Hospital of Central South University and 
Hunan province tumour Hospital in Changsha Hunan. The demographic and basic clinical 
characteristics were collected for each patient. The data included age, smoking status, 
histology, gender, stage, chemotherapeutic regimen, and Eastern Cooperative Oncology 
Group Performance Status (ECOG PS). The information is shown in the table 5.1.1. 
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Table 5.1.1. Main clinical characteristics for the lung cancer patients receiving platinum-based chemotherapy 
treatment.  
Characteristics 
Responders Non-responders 
N (%) N (%) 
Total 100 100.0 235 100.0 
Age (years)     
≤55 52 52% 98 42% 
>55 48 48% 137 58% 
Gender     
Male 79 79% 174 74% 
Female 21 21% 61 26% 
Histology     
ESCC 39 39% 132 56% 
EAC 61 61% 103 44% 
Stage (non-small cell lung carcinoma)     
I-II 5 5% 15 6% 
III-IV 95 95% 220 94% 
Smoking     
Yes 58 58% 105 45% 
No 42 42% 130 55% 
Polymorphism     
Wild Type 14 14% 49 21% 
Heterozygous 36 36% 66 29% 
Homozygous 50 50% 120 51% 
Chemotherapeutic regimen     
Cisplatin 39 39% 114 49% 
Carboplatin 61 61% 121 51% 
ECOG     
0-1 96 96% 233 99% 
>1 4 4% 2 1% 
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The following patients were included in the study: 
• Patients who were diagnosed lung cancer by histology or cytology;  
• Patients who had never received any radical or biological therapy before first line 
chemotherapy; 
• All patients who had received at least two cycles of first line chemotherapy;  
• All patients who had received a follow up exam in six months. 
 The following patients were excluded:  
• Patients who were pregnant or feeding new-borns; 
• Patients who had been diagnosed with other malignancies; 
• Patients who had brain metastases; 
• Patients who had active infections. 
Patients enrolled in this study received first-line platinum-based chemotherapy. Patients were 
treated with different drugs that were grouped either cisplatin or carboplatin. (Detailed in 
table 5.1.2).  
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Table 5.1.2. Drugs used by patents in present study. 
Number Drug name Shortcut Number of patients % Category 
 
1 pemetrexed disodium/ cisplatin PP 80 24%               Cisplatin 
2 Gemcitabine/ paclitaxel DP 141 42% Carboplatin 
3 Docetaxel/ cisplatin DP 52 15%               Cisplatin 
4 Paclitaxel/ carboplatin TP 22 7% Carboplatin 
5 Gemcitabine/ carboplatin NP 27 8% Carboplatin 
6 vinorelbine/cisplatin NP 13 4%                Cisplatin 
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Chemotherapy response was assessed after the first two cycles of chemotherapy according to 
the RECIST guideline (version 1.1) for solid tumours. That guideline provides the deﬁnitions 
of the criteria used to determine objective tumour response for target lesions. Complete 
Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether 
target or non-target) must have a reduction in short axis to <10 mm. Partial Response (PR): At 
least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline 
sum diameters. Progressive Disease (PD): At least a 20% increase in the sum of diameters of 
target lesions, taking as reference the smallest sum on study (this includes the baseline sum if 
that is the smallest on study). In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm. Stable Disease (SD): Neither sufﬁcient 
shrinkage to qualify for PR nor sufﬁcient increase to qualify for PD, taking as reference the 
smallest sum diameters while on study. The patients that showed CR or PR were regarded as 
platinum sensitive, while, in the case of PD or SD, were regarded as platinum resistant [50]. 
Stage of tumour was determined by the cTNM classification of the Union Internationale 
contre le Cancer (UICC) [51] for non-small cell lung cancer patients. In this study, four stages 
of cancer were classified into two groups as I-II and III-IV. 
 
6.2. Tagging SNP selection 
This study is related to the ongoing research at the Institute of Clinical Pharmacology, in 
which the association of gene polymorphisms with chemotherapy is investigated. The DNA 
samples analysed were obtained from non-small cell lung cancer (NSCLC) patients that were 
treated by platinum-based chemotherapy. The work was focused on a rare genetic variant in 
PDCD6IP. The SNP selected for this study was rs3183982. 
The selected SNP satisfied the following criteria:  
(1) The SNP was chosen from the International HapMap Project Phase II database of Chinese 
population (http://www.hapmap.org/); [51] 
 (2) SNP was a haplotype tagger SNP; 
 (3) Minor allele frequency (MAF) was larger than 5% in Hunan Province population China; 
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6.3.  DNA extraction and genotyping procedure 
Approximately 5 ml venous blood was collected from each patient for genetic studies. 
Genomic DNA was extracted from whole peripheral blood using E.Z.N.A. SQ Blood Kit II 
(Omegabio-tek) according to the following protocols. 
 
6.3.1. Genomic DNA extraction 
• Before starting the procedure frozen blood was thawed quickly in a 37°C water bath 
with gentle agitation and stored on ice. 
• 5 ml blood were added to a nuclease-free 50 ml centrifuge tube containing 30 ml (5 
fold the volume of blood) Buffer NL (in order to lyse the plasma membrane). The 
mixture was centrifuged at 2000 x g for 5 minutes at room temperature. 
• The supernatant was discarded and the tube was left inverted on a clean piece of 
absorbent paper for 2 min. 
• 5 ml Buffer XL (containing chemotropic salt and proteinase K) were added to the tube 
containing the nuclei pellet, and the pellet was ressuspended through use of a vortex 
agitator.   
• The suspension was incubated at 65°C for 10-15 minutes in a heating block. 
• 5 ml of isopropanol were added to the lysate, and mixed by inversion until the DNA 
precipitate become visible as threads or clumps, followed by centrifugation at 2000 x 
g for 5 minutes at room temperature. 
• The supernatant was poured out and the tube drained on a clean absorbent paper towel. 
The pellet was washed by addition of 5 ml 70% ethanol and vortex agitation, followed 
by centrifugation at 2000 x g for 5 minutes at room temperature. The ethanol solution 
was carefully poured out. 
• The pellet was dried for 10-15 min, with the tube inverted on a clean absorbent paper 
towel. 
• 1 ml of DNA rehydration solution was added, followed by incubation at 65°C for 1 
hour to rehydrate DNA. The purified DNA samples were stored at -20°C. 
Primers were designed by using Primer3 software. Primer sequences were forward primer 
5’ – TGTTTTGACTCCTATTGGATTTT - 3’, reverse primer 5’- 
CATGTACTTCATACCTTTGTGCC – 3’. The gene is located 3p22, the exon category. 
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The presence of the variant allele creates a TaqI restriction site. The PCR product (361bp) 
was therefore digested with TaqαI an E. coli strain that carries a TaqαI (overproducing 
plasmid) that has a two amino acid replacement at its amino terminus. The enzyme has a 
higher level of expression without interfering with its catalytic properties, resulting in 
three fragments: carry AA 360bp, AG 260bp + 230bp + 130bp, GG 230bp + 130bp. 
 
 
Picture 5.3.1.1. The PDCD6IP gene with the location of the selected polymorphism 
 
6.3.2. Procedures of genotyping by PCR-RELP:  
a) Polymerase chain reaction (PCR) amplification 
 Components of the reaction mixture: 
• 10.3μL HPLC grade Water (BioSune), 
• 2μL 10 × PCR Buffer, (TransGEN)  
• 0.3 μL 25mM dNTP Mix, (CutSmart) 
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• 0.2μL 0.5mM Primer Mix, (BioSune) 
• 0.2μL 5 U/μL HotStart Taq, (BioLabs) 
• Approximately 2μL 10 ng/μL DNA in a final volume 15μL. Yes, professor 
they select randomly around 20 samples and measure DNA concentration with 
nanodrop and it was always very similar so they always do like this.  
 PCR conditions (thermocycler 6321, Eppendorf): 
• denaturation at 94 ℃ for 15 minutes, 
• 35 cycles (desnaturation at 94ºC  for 45 seconds, annealing at 59 ℃ for 45 seconds 
and extension at 72 ℃ for 45 seconds),  
• additional extension at 72 ℃ for 10min. 
• samples were kept  at 4 ℃ until analysis 
b) RFLP (Restriction Length Fragment Polymorphism) analysis 
Components of the reaction mixture: 
• 15.5 μL Nanopure water, 
• 0.5μL cutSmart enzyme TaqαI 
• 2μL 10 × NEB Buffer 
• 2μL DNA in a final volume 20μL.  
Samples were incubated at 65ºC for 60 minutes, and then kept at 4ºC until analysis. 
c) DNA electrophoresis: 
Materials:   
• Agarose 1.5% 
• 1x TAE - ethidium bromide, (0.04 mol/L Tris-HCL and 0.001 mol/L EDTA) 
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• loading dye, (gel red) 
•  marker, (TransGEN) 
• sample DNA (a digestion product)  
The conditions were: 
• current 70 mA, 
• tension 150V, 
• time 25-30 minutes. 
Fragment analysis; the allelic discrimination of the SNP was determined by the numbers 
of fragments and relative positions in the gels. Restriction patterns were analysed by using 
Dongsheng Bio-Imaging system. Figure 5.3.2.1. Shows the different possible genotype 
patterns, resulting from the possible 260bp, 230bp and 130bp. Figure 5.3.2.2. Shows 
actual results, representative of different samples analysed.  
 
 
Picture 5.3.2.1.  Expected results after DNA electrophoresis.  
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Picture 5.3.2.2. The results after DNA electrophoresis.  
 
6.3.3.  Statistical analysis 
Genotypic frequencies were tested for the Hardy - Weinberg Equilibrium (HWE) by using 
the chi - square test. The association of genotypes and chemotherapy response was tested 
with logistic regression analysis. The potential covariates on chemotherapy response were 
selected by using binary logistic regression. Age, sex, smoking status, chemotherapeutic 
regimen, and classification, ECOG and histology type were considered as covariates. All the 
above analysis were performed using SPSS 13.0 (SPSS Inc., Chicago, Illinois, USA). Odds 
ratios (OR) with their 95% confidence intervals (CIs) were used to assess response to 
chemotherapy. P<0.05 was considered as significant. The relationship of the SNP with 
response of chemotherapy in different categories, was performed by the stratification 
analysis by SPSS 13.0. 
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7. RESULTS 
 
7.1.  Patient Characteristics 
 A total of 335 lung cancer patients were recruited in this study. All the people were Chinese 
with the average age of 55.3±9.2 range (22-76), in the work examined 150 patients  (44.8%) 
which were ≤55 years old, and 185 (55.2%) >55 years old. The basic demographic and 
clinical characteristics were shown in Table 5.1.1. and 6.1.1. The non-small cell lung 
carcinoma patients were more likely to be non-responders than responders, the number of 
responders (CR or PR) were 100 and non-responders (PD or SD) were 235. The patient 
sample comprised 253 (75.5%) males and 82 (24.5%) females. In which concerns the 
differentiation in the histology 174 patients had  esophageal squamous cell carcinoma (ESCC) 
and 161 Erythema annulare centrifugum (EAC).The majority 315 (95.0%) patients were on 
III-IV stage of NSCLC, when only 20 (5.0%) were stage I-II. The majority of patients were 
smokers 188 (56.1%). All patients received platinum-based chemotherapy, cisplatin-based 
was 153(45.7%) and carboplatin-based was 182(44.3%). The ratio of ECOG 0-1 was in 329 
patients and was lower in responders than non-responders (96 vs 99%, P=0.033). 
There were no significant differences between responders and non-responders in gender, stage 
of cancer, smoking status and chemotherapy regiment, indicating that the populations were 
adequately matched. Covariate analysis showed that age (P-value 0.037), histology (0.022) 
and ECOG (0.033) may be considered statistically significant risk factors on platinum-based 
chemotherapy efficacy in all population.  
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Table 6.1.1. Main clinical characteristics of lung cancer patients. 
Characteristics 
Summary P-Value OR (95% C.I).  
N (%)    
Total 335 100.0%    
Age (years)   0.037 1.72(1.03-2.86) 
≤55 150 44.8%    
>55 185 55.2%    
Gender   0.321 1.46(0.69-3.11) 
Male 253 75.5%    
Female 82 24.5%    
Histology   0.022 0.51(0.28-0.91) 
ESCC 174 51.9%    
EAC 161 48.1%    
Stage (non-small cell lung carcinoma)   0.267 0.85(0.49-1.48) 
I-II 20 5.0%    
III-IV 315 95.0%    
Smoking   0.482 1.27(0.69-3.11) 
Yes 188 56.1%    
No 147 42.9%    
Chemotherapeutic regimen   0.560 0.85(0.49-1.48) 
Cisplatin 
Carboplatin 
153 
182 
45.7% 
44.3% 
   
Polimorphism     
Wild Type 
Heterozygous 
63 
102 
18.8% 
30.4% 
   
Homozygous 170 50.8%    
ECOG   0.033 0.146(0.25-0.85) 
0-1 
>1 
329 
6 
98.2% 
1.8% 
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7.2. Prevalence of the PDCD6IP rs3183982 SNP  
The SNP (3183982) information of PDCD6IP gene was shown in table 6.2.1. The call rate 
was 100%. The minor allele frequency was G=0.3303/1654. . The genotype 
frequencies agreed with the Hardy-Weinberg equilibrium. This mean that for rs 3183982, 
minor allele is ‘G’ and has a frequency of 33.03% in the 1000Genome phase 1 population 
and that ‘g’ is observed 1654 times. 
 
 
 
Table 6.2.1. The gene polymorphisms examined in this study. 
Gene dbSNP Call Rate(%) Polymorphism MAF HWE P 
PDCD6IP rs3183982 335(100) A/G G=0.3303/1654 0.60 
 
MAF: minor allele frequency 
HWE P: p value for Hardy-Weinberg test 
 
 
7.3. Relation of PDCD6IP gene polymorphism with platinum-based 
chemotherapy response  
The frequency distribution of the possible genotypes observed for all subjects was listed in 
table 6.3.1, that summarises the results of the analysis of the rs3183982 SNP in all 335 
lung cancer patients. In this study after analysis 63 patients (18.8%) were classified base 
on pictures obtained after electrophoresis as carriers of the wild-type genotype, 103 
(30.4%) homozygous for the variant, 170 (50.8%) heterozygous. 
The rs31839825 SNP showed a significant association with chemotherapy response when 
considering the additive model (OR=0.67, P=0.033). No statistically significant 
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association was found between SNP in both recessive, dominant models and 
chemotherapy response table 6.3.2. 
 
Table 6.3.1. Allele frequencies of the gene polymorphism in 335 patients. 
Gene Polymorphism Wild-type 
(N/%) 
Heterozygous (N/%) Homozygous(N/%) 
PDCD6IP rs3183982 53(18.8) 102(30.4) 170(50.8) 
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Table 6.3.2.  Association of single nucleotide polymorphism and platinum-based chemotherapy response in all lung cancer patients. 
The values in bold were considered statistically significant.  
N=Number of patients. 
 
 
 
 
Gene Polymorphisms Genotype Responders Non-responders Additive Dominant Recessive 
   N(%) N(%) OR(95%CI) P value OR(95%CI) P value OR(95%CI) P value 
PDCD6IP rs3183982 AA 14(14) 49(21) 0.67(0.47-0.97) 0.033  0.56(0.29-1.09) 0.089 0.62(0.37-1.04) 0.072 
  AG 50(50) 120(51)       
  GG  36(36) 66(28)       
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Esophageal squamous cell carcinoma (ESCC) and Erythema annulare centrifugum (EAC) are 
very different biologically [52]. Smokers and non-smokers, younger and elders, male and 
female, chemotherapeutic regiment (cisplatin and carboplatin) also may be different in 
chemotherapy response. 
To further investigate the relationship of the SNP with response to chemotherapy, it was 
considered that there could be some associations among subgroups. To investigate this 
hypothesis, a stratification analysis was performed (Table 6.3.3.). The subgroups were divided 
into ESCC or EAC by histology, smoking or non-smoking by smoking status, ≤55 years old 
or ＞55 years old by age, male or female by gender, I-II or III-IV by stage of cancer, cisplatin 
or carboplatin by chemotherapeutic regimen. There were few results that showed significant 
associations with chemotherapy response: for stage I-II in additive (OR=1.89, P=0.017) and 
dominant (OR=2.1, P=0.014) models, for EAC in additive model (OR=0.83, P=0.041), for 
non-smoking (OR=0.47, P=0.048), and for cisplatin (OR=0.51, P=0.046) in recessive model. 
In this study, the number of independent variables for PDCD6IP is 6. The SNP was analyzed 
in three genetic models. To take into account the problem of multiple testing, the significance 
threshold is therefore 0.05/ (3*6) = 0.0027. Using this threshold, no association remained 
significant. 
 
 
 
Table 6.3.3. Stratification analyses of the associations of the polymorphism and chemotherapy efficacy in 
                      a) Dominant (A), 
                      b) Recessive (B),  
                      c) Additive(C) models. 
 
 
 
 
 
Page | 65 
 
a) 
A additive 
   Variable  
                 Characteristics P-Value  95% C.I. for EXP (B) 
OR 
 Histology ESCC 0.306 0.77(0.46-1.27) 
EAC 0.041 0.83(0.45-1.53) 
 Smoking status Smoking 0.352 0.80(0.50-1.28) 
Non-smoking 0.147 0.68(0.40-1.15) 
 Age (year) ≤55 0.226 0.75(0.47-2.00) 
<55 0.489 0.85(0.54-1.35) 
 Gender Male 0.156 0.76(0.52-1.11) 
Female 0.293 0.63(0.27-1.49) 
 Stage I-II 0.017 1.89(1.12-3.17) 
III-IV 0.076 0.74(0.52-1.03) 
 Chemotherapy 
regimen 
Cisplatin 0.212 0.70(0.41-1.22) 
Carboplatin 0.305 0.79(0.51-1.23) 
 
 
b) 
B recessive 
   Variable  
                 Characteristics P-Value  95% C.I. for EXP (B) 
OR 
 Histology ESCC 0.318 0.70(0.34-1.42) 
EAC 0.312 0.69(0.33-1.42) 
 Smoking status Smoking 0.949 0.98(0.49-1.96) 
Non-smoking 0.048 0.47(0.21-1.01) 
 Age (year) ≤55 0.262 0.69(0.36-1.32) 
<55 0.956 0.98(0.49-1.97) 
 Gender Male 0.312 0.75(0.52-1.11) 
Female 0.306 0.53(0.16-1.79) 
 Stage I-II 0.419 4.14(0.13-13.63) 
III-IV 0.211 0.72(0.44-1.20) 
 Chemotherapy 
regimen 
Cisplatin 0.046 0.51(0.24-1.08) 
Carboplatin 0.920 0.96(0.48-1.93) 
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c) 
C Dominant 
   Variable  
                 Characteristics P-Value  95% C.I. for EXP (B) 
OR 
 Histology ESCC 0.784 0.79(0.35-2.20) 
EAC 0.260 0.63(0.28-1.41) 
 Smoking status Smoking 0.110 0.48(0.19-1.18) 
Non-smoking 0.931 1.04(0.43-2.51) 
 Age (year) ≤55 0.945 0.97(0.45-2.09) 
<55 0.337 0.66(0.29-1.54) 
 Gender Male 0.339 0.72(0.37-1.41) 
Female 0.527 0.62(0.14-2.76) 
 Stage I-II 0.014 2.10(1.12-3.78) 
III-IV 0.153 0.65(0.35-1.18) 
 Chemotherapy 
regimen 
Cisplatin 0.711 1.20(0.45-3.17) 
Carboplatin 0.147 0.57(0.27-1.22) 
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8. CONCLUSION  
 
The fact that chemo sensitivity differs from person to person reflects a limited understanding 
of the molecular mechanism of lung carcinogenesis. Existing evidence suggests that there are 
many differences among patient subgroups that may determine individual susceptibility to 
lung cancer. Nowadays individualized therapies are becoming more and more popular. There 
are many reasons to think that is the future for cancer therapies. Out of the entire group of 
patients taken into this study, 70% were resistant to the platinum based chemotherapy which 
means that the treatment is not effective enough to beat the cancer. Almost 95% of patients 
were stage III-IV, suggesting that the diagnosis of NSCLC is poor, people are being 
diagnosed too late and have already developed metastasis.  There is a lack of adequate tests 
and well-characterized genetic markers for the diagnostics and characterization of 
chemotherapy resistance in lung cancer. 
 Results between responders and non-responders have shown significant differences in age, 
histology, and ECOG that might suggest that acquisition of resistance can be in future more 
deeply investigated in different age groups and histology. This can have a consequence in 
efficiency, response and future survival rate for patients so it is extremely important to 
investigate these variations. These results show that there is a correlation between response 
and resistance to platinum based chemotherapy. They also suggest that there is a connection 
between resistance to a drug and the histology. Henceforth, these findings open the way for 
new studies on the use of different treatment in patients with ESCC and EAC. There is a great 
need for new therapies and new biomarkers focusing on molecular targets helping to identify 
patients who will benefit from therapy 
 
 
The distribution of genotypes for the SNP analysed in the present study, PDCD6IP rs3183982, 
shows a significant association with chemotherapy response. Our results showed that this 
might clarify the actual association between the gene polymorphism and lung cancer risk or 
chemo sensitivity. The knowledge about the association of rs3183982 SNP in PDCD6IP with 
chemotherapy resistance could be the basis for choosing an alternative treatment in the 
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patients that have that polymorphism. In the future, this SNP might be used as a marker 
helping to diagnose lung cancer in early stage, and maybe even changes in the cells before the 
cancer cells start proliferation.  
 
However, our results require future verification and investigation. Researchers discovered that 
there are many proteins whose expression is associated with platinum resistant treatment [53]. 
The stratification analysis of the presence of rs3183982 SNP showed significant associations 
among subgroups: for stage I-II, for EAC, for non-smoking, and for cisplatin. This is further 
proof that histology and platinum based chemotherapy are being affected by SNP. Over the 
years, there were plenty of studies that explored the relationship of polymorphisms of 
candidate genes with chemotherapy response (54, 55, 56). However, the associations between 
chemotherapy response and rs3183982 in PDCD6IP polymorphism have not been detected in 
any population based on a candidate gene approach. We presented here the ﬁrst case–control 
study evaluating the association between the rs3183982 polymorphism within the promoter of 
PDCD6IP and chemotherapy response. 
 In this study, I investigated the association of the transporter gene PDCD6IP SNP with 
platinum-based chemotherapy response. Our results showed that SNPs rs3183982 might be 
related with chemotherapy response in lung cancer patients. More studies need to be 
performed to investigate the potential linking of rs3183982 polymorphism in PDCD6IP 
encoding protein required for apoptosis with cancer progression and prognosis. Future 
investigations should be focused on the level of the transcriptional activity of PDCD6IP, 
using luciferase assays in transiently transfected NSCLC cells. 
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